Imatinib for chronic myeloid leukaemia: a NICE mess
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference4 articles.
1. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia;Goldman;Lancet,2000
2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome;Druker;N Engl J Med,2001
3. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001
4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification;Gorre;Science,2001
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Multi-Targeted Anticancer Agents;Current Topics in Medicinal Chemistry;2017-11-20
2. Fixing Legitimacy? The Case of NICE and the National Health Service;Health Policy and Politics;2016-04-22
3. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study;European Journal of Cancer;2015-10
4. The advantages of being called NICE: a systematic review of journal article titles using the acronym for the National Institute for Health and Clinical Excellence;Journal of Public Health;2008-12-24
5. Comparing Patient Access to Pharmaceuticals in the UK and US;Applied Health Economics and Health Policy;2006
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3